A Phase I Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of Intranasal Dexmedetomidine in Healthy Subjects
Phase of Trial: Phase I
Latest Information Update: 25 Jan 2018
Price : $35 *
At a glance
- Drugs Dexmedetomidine (Primary) ; Dexmedetomidine (Primary)
- Indications Sedation
- Focus Adverse reactions
- Sponsors Jiangsu Hengrui Medicine Co.
- 22 Jan 2018 Planned End Date changed from 1 Dec 2017 to 1 Jul 2018.
- 22 Jan 2018 Planned primary completion date changed from 1 Dec 2017 to 1 Jul 2018.
- 05 Oct 2017 New trial record